Journals / Solunum / 2008 / Cilt: 10 - Sayı: 1

Acute renal failure due to continuous rifampicin therapy

Sürekli rifampisin tedavisine bağlı akut böbrek yetmezliği

Journal
Solunum
Pages
67–70
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient had normal renal functions after discontinuation of rifampicin.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Rifampicin is one of the standart drugs of tuberculosis treatment.
📊
Key Findings & Data:ARF that has developed during the four-drug tuberculosis regimen, given for sputum positive lung tuberculosis, including streptomycin 1 gr/day and rifampicin 600 mgr/day, has been evaluated at this study.
💡
Conclusion & Impact:The patient had normal renal functions after discontinuation of rifampicin.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Erkek · Rifampin · Genç erişkin

Abstract

Rifampicin is one of the standart drugs of tuberculosis treatment. Acute renal failure (ARF) rarely may develop due to rifampicin. ARF, typically, develops on reintroduction of the drug or during intermittent therapy. However, it also has been reported during continuous rifampicin therapy. ARF that has developed during the four-drug tuberculosis regimen, given for sputum positive lung tuberculosis, including streptomycin 1 gr/day and rifampicin 600 mgr/day, has been evaluated at this study. Although streptomycin was stopped since the patient that had mildly high levels of urea and creatinine since the begining, a renal biopsy was performed. Histopathologic examination demonstrated an tubulointerstitial nephritis. Rifampicin was continued at the beginning, because tuberculosis disease of the patient was severe and the patient was not considered to have rifampicin toxicity. Since rifampicin toxicity is seen rarely in continuous therapy and we did not detect any objective way of immunoallergic damage the renal toxicity could not be related to rifampicin. We decided that it was a renal failure caused by rifampicin, according to the biopsy result. The patient had normal renal functions after discontinuation of rifampicin.

Özet

Rifampisin, tüberküloz tedavisinin standart bir parçasıdır. Rifampisine bağlı akut böbrek yetmezliği (ABY), nadiren gelişir. ABY, tipik olarak, aralıklı veya belli bir süre sonra tekrar rifampisin kullanımı sırasında gelişmektedir. Ancak sürekli (günlük) rifampisin kullanımı sırasında da ABY gelişen olgular bildirilmiştir. Bu çalışmada, yayma pozitif akciğer tüberkülozu tanısı ile rifampisin 600 mg/gün ve streptomisin 1 g/gün içeren dörtlü tedavi sırasında gelişen ABY değerlendirilmiştir. Streptomisin kesilmesine rağmen, üre ve kreatinin değerleri başlangıçtan beri hafif yüksek seyreden hastaya renal biyopsi yapılmıştır. Histopatolojik görünüm tübülointerstisyel nefrit ile uyumlu bulunmuştur. Başlangıçta tüberkülozun ağır olması ve rifampisin toksisitesinin düşünülmemesi nedeniyle rifampisine devam edilmiştir. Sürekli kullanımda çok nadir olması ve immunoallerjik bir mekanizmanın objektif olarak ortaya konamaması nedeniyle renal toksisite, rifampisin ile ilişkilendirilmemiştir. Biyopsi sonucu ile değerlendirilen hastada rifampisine bağlı ABY düşünülmüş ve rifampisinin kesilmesi ile birlikte günler içinde renal fonksiyon parametreleri normale dönmüştür.

🔖

Cite This Article

OKUTAN, O., TAŞ, D., ATASOYLU, E. M., HAHOĞLU, A., ÇİFTÇİ, F., KARTALOĞLU, Z. (2008). Acute renal failure due to continuous rifampicin therapy. Solunum, Cilt: 10 - Sayı: 1, 67–70. https://ajindex.com/articles/314415

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. World Health Organization. Treatment of tuberculosis: Guidelines for national programmes. Third edition Geneva 2003: 28
  2. Özkara ş. Klinisyenler için tüberküloz kılavuzu (Iseman DI, çeviri) 1. basım. Ankara: Nobel Tıp Kitabevleri, 2002:280- 3
  3. Covic A, Goldsmith DJA, Segall L, et al. Rifampicin induced acute renal failure: a series of 60 patients. Nephrol Dial Transplant 1998; 13: 924- 9
  4. De Vriese AS, RobbrechtDL, Vanholder RC, et al. Rifampicinassociated acute renal failure: Pathophysiologic, immunologic, and clinical features. Am J Kidney Dis 1998; 31: 108-15
  5. Muthukumar T, Jayakumar M, Fernando EM, et al. Acute renal failure due to rifampicin: A study of 25 patients. Am J Kidney Dis 2002; 40: 690- 6
  6. Erten Y, şahiner ş, Bodur H, ve ark. Rifampisine bağlı akut böbrek yetmezliği. T Klin Tıp Bilimleri 2003; 23:38- 40
  7. Power DA, Russel G, Smith FWe, et al. Acute renal failure due to continuous rifampicin. Clin Nephrol 1983; 20:155- 9
  8. Nessi R, Bonoldi GL, Redaelli B, di Filippo G. Acute renal failure rifampicin: a case report and survey of the literature. Nehron 1976; 16: 148- 59. (abstract
  9. Cohn JR, Fye DL, Sills JM, Francos GC. Rifampicin-induced renal failure. Tubercle 1985; 66: 289- 93
  10. Banu Rekha VV, Santha T, JawaharMS. Rifampicin-induced renal toxicity during retreatment of patientswith pulmonary tuberculosis. JAPI 2005; 53: 811- 3
  11. Öztuna I, BüyükşirinM, Kömürcüolu B, ve ark. Rifampisine bağlı akut böbrek yetmezliği. Solunum 2003; 5: 227- 9
  12. Bicik Z, Ersan S. Akut renal yetmezlik. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 1999; 3: 113- 7
  13. Rossert JA, Fischer EA. Acute interstitial nephritis. In: Johnson RJ, Feehally J, eds. Comprehensive clinical nephrology. 2nd Edition. Mosby: 2003: 769- 74
  14. Palomino J, Pachon J. Aminoglycosides. Enfermm ‹nfect Microbiol Clin 2003; 21: 105- 14
  15. Mingeot Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrobiol Agents Chemother 1999;43: 1003- 12
  16. Sanwikarja S, Kauffmann RH, te Velde J, Serlie J. Tubulointerstitial nephritis associated with pyrazinamide. Neth J Med 1989; 34: 40- 6. (Abstract)